20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Developing a Gene Expression Model for Predicting Ventilator-Associated Pneumonia in Trauma Patients: A Pilot Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Ventilator-associated pneumonia (VAP) carries significant mortality and morbidity. Predicting which patients will become infected could lead to measures to reduce the incidence of VAP.

          Methodology/Principal Findings

          The goal was to begin constructing a model for VAP prediction in critically-injured trauma patients, and to identify differentially expressed genes in patients who go on to develop VAP compared to similar patients who do not. Gene expression profiles of lipopolysaccharide stimulated blood cells in critically injured trauma patients that went on to develop ventilator-associated pneumonia (n = 10) was compared to those that never developed the infection (n = 10). Eight hundred and ten genes were differentially expressed between the two groups (ANOVA, P<0.05) and further analyzed by hierarchical clustering and principal component analysis. Functional analysis using Gene Ontology and KEGG classifications revealed enrichment in multiple categories including regulation of protein translation, regulation of protease activity, and response to bacterial infection. A logistic regression model was developed that accurately predicted critically-injured trauma patients that went on to develop VAP (VAP+) and those that did not (VAP−). Five genes (PIK3R3, ATP2A1, PI3, ADAM8, and HCN4) were common to all top 20 significant genes that were identified from all independent training sets in the cross validation. Hierarchical clustering using these five genes accurately categorized 95% of patients and PCA visualization demonstrated two discernable groups (VAP+ and VAP−).

          Conclusions/Significance

          A logistic regression model using cross-validation accurately predicted patients that developed ventilator-associated pneumonia and should now be tested on a larger cohort of trauma patients.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Phosphoinositide 3-kinase: diverse roles in immune cell activation.

          Cells of the immune system carry out diverse functions that are controlled by surface receptors for antigen, costimulatory molecules, cytokines, chemokines, and other ligands. A shared feature of signal transduction downstream of most receptors on immune cells, as in nonhematopoietic cell types, is the activation of phosphoinositide 3-kinase (PI3K). The mechanism by which this common signaling event is elicited by distinct receptors and contributes to unique functional outcomes is an intriguing puzzle. Understanding how specificity is achieved in PI3K signaling is of particular significance because altered regulation of this pathway is observed in many disease states, including leukemia and lymphoma. Here we review recent advances in the understanding of PI3K signaling mechanisms in different immune cells and receptor systems. We emphasize the concept that PI3K and its products are components of complex networks of interacting proteins and second messengers, rather than simple links in linear signaling cascades.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.

            The regulation of the activity of potentially harmful proteinases secreted by neutrophils during inflammation is important for the prevention of excessive tissue injury. Secretory leukocyte proteinase inhibitor (SLPI), also called antileukoprotease (ALP) or mucus proteinase inhibitor (MPI), is a serine proteinase inhibitor that has been found in a variety of mucous secretions and that is secreted by bronchial epithelial cells. We recently reported the presence of SLPI and of an elastase-specific inhibitor (ESI), also called elafin, in the supernatants of two cell lines, NCI-H322 and A549, which have features of Clara cells and type II alveolar cells, respectively. We showed in addition that epithelial cell lines produce the elastase-specific inhibitor as a 12 to 16 kD precursor of the elafin molecule (6 kD) called pre-elafin. In the present study, we show that NCI-H322 cells produced higher amounts of both inhibitors than A549 cells and that basal production of SLPI in both cell lines is higher than the production of elafin/pre-elafin. In addition, we show that interleukin-1 beta and tumor necrosis factor induce significant SLPI expression and are major inducers of elafin/pre-elafin expression. Moreover, induction is greater in A549 cells than in NCI-H322 cells. The implications of these findings for the peripheral airways are twofold: (1) alveolar epithelial cells may respond to cytokines secreted during the onset of inflammation by increasing their antiprotease shield; (2) elafin/pre-elafin seems to be a true local "acute phase reactant" whereas SLPI, in comparison, may be less responsive to local inflammatory mediators.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?

              Class IB phosphatidylinositol 3-kinase p110gamma (PI3Kgamma) has gained increasing attention as a promising drug target for the treatment of inflammatory disease. Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up potentially huge opportunities for these drugs. Several companies have been pursuing small-molecule PI3Kgamma inhibitor projects, but none of them has progressed to the clinic yet. Here, we discuss the insights gained so far and the main challenges that are emerging on the path to developing PI3Kgamma inhibitors for the treatment of human disease.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2012
                15 August 2012
                : 7
                : 8
                : e42065
                Affiliations
                [1 ]Department of Clinical Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
                [2 ]Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
                [3 ]Department of Surgery, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
                [4 ]Department of Biological Sciences, The University of Memphis, Memphis, Tennessee, United States of America
                [5 ]Bioinformatics Program, The University of Memphis, Memphis, Tennessee, United States of America
                National Taiwan University Hospital, Taiwan
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: JMS GCW LX BM RH MAC TCF. Performed the experiments: JMS GCW LET. Analyzed the data: JMS GCW LX RH. Contributed reagents/materials/analysis tools: JMS GCW LET LX BM RH. Wrote the paper: JMS GCW LX RH MAC TCF. Revision of the manuscript: JMS GCW LX LET BM RH MAC TCF. Final approval of the manuscript: JMS GCW LX LET BM MAC TCF.

                Article
                PONE-D-12-02143
                10.1371/journal.pone.0042065
                3419717
                22916119
                ad777982-cf1d-4c7b-b32c-435141b10968
                Copyright @ 2012

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 23 January 2012
                : 2 July 2012
                Page count
                Pages: 7
                Funding
                This study was funded by the Society of Infectious Diseases Pharmacists/Cubist Research Award. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology
                Computational Biology
                Molecular Genetics
                Gene Expression
                Microarrays
                Genetics
                Gene Expression
                Molecular Cell Biology
                Gene Expression
                Computer Science
                Computer Modeling
                Medicine
                Critical Care and Emergency Medicine
                Infectious Diseases
                Bacterial Diseases
                Bacterial Pneumonia

                Uncategorized
                Uncategorized

                Comments

                Comment on this article